Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.
Weight loss medications Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.
Wegovy, Ozempic added to list of drugs where the federal government will try winning discounts from manufacturers.
Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...
Apple stock rises after falling Thursday by the most since August, Alphabet stock is up after the Supreme Court upholds a ban ...
Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...
By Berkeley Lovelace Jr. The Biden administration on Friday released the next round of prescription drugs selected ...
The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...
The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback